DATA GRAPHICS | Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
As Eylea and Lucentis lose market share in age-related macular degeneration, their makers’ next-generation products are offsetting the decline — in Roche’s case, even expanding the franchise — as biosimilars struggle to gain traction.
Through the introduction of Eylea HD, a higher dose product with less frequent administration than the original Eylea aflibercept, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Bayer AG (Xetra:BAYN) have managed to preserve most of their AMD market share. The $9.5 billion in combined sales of Eylea and Eylea HD in 2024 was just shy of Eylea’s $9.6 billion in 2022. ...